rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
Pt 3
|
pubmed:dateCreated |
2006-12-15
|
pubmed:abstractText |
To date, the neurotransmitter(s) and pathways involved in cutaneous active vasodilatation are not fully understood. The purpose of this study was to determine the potential involvement of neurokinin-1 (NK(1)) receptors to active vasodilatation. Our experimental model exploited our previous findings that repeated microdialysis infusions of substance P desensitize the NK(1) receptors and that substance P-induced vasodilatation contains a substantial nitric oxide (NO) component. Eleven subjects were equipped with four microdialysis fibres on the ventral forearm. Site 1 served as a control and received a continuous infusion of Ringer solution. Site 2 received a continuous infusion of 10 mM L-NAME to inhibit NO synthase. Site 3 received a 10 microm dose of substance P to desensitize the NK(1) receptors prior to whole-body heating. Site 4 received a 10 microm dose of substance P combined with 10 mM L-NAME. Red blood cell (RBC) flux was measured via laser-Doppler flowmetry, and cutaneous vascular conductance (CVC) was calculated as RBC flux/mean arterial pressure and normalized to maximal vasodilatation via 28 mM sodium nitroprusside. Substance P was infused for 15 min at 4 microl min(-1) in sites 3 and 4, and skin blood flow was allowed to return to baseline (approximately 45-60 min). Subjects then underwent a period of whole-body heat stress to raise oral temperature 0.8-1.0 degrees C above baseline. Pretreatment with substance P increased CVC to 48 +/- 2% CVC(max), which was significantly greater than for sites pretreated with substance P combined with L-NAME (27 +/- 2% CVC(max); P < 0.001). During whole-body heating, CVC in control sites increased to 69 +/- 3% CVC(max). Sites pretreated with substance P (48 +/- 3% CVC(max)) were significantly reduced compared to control sites (P < 0.001). The CVC response to whole-body heat stress in L-NAME sites was significantly reduced (32 +/- 3% CVC(max); P < 0.001) compared to both control sites and sites pretreated with substance P. The CVC response to whole-body heating was nearly abolished in sites pretreated with substance P combined with L-NAME (20 +/- 2% CVC(max)) and was significantly reduced compared to the other three sites (all P < 0.001). These data suggest NK(1) receptors contribute to active vasodilatation and that combined NK(1) receptor desensitization and NO synthase inhibition further diminishes active vasodilatation.
|
pubmed:grant |
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-10194201,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-10336084,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-10658012,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-11121135,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-11568143,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-12381749,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-12391110,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-12651918,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-12679350,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-12692141,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-12808346,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-12847205,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-12849662,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-13414140,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-13429515,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-13564431,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-14715681,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-15155712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-15375193,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-16109832,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-16123103,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-16484440,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-1692268,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-1702831,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-1706332,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-17095556,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-1711051,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-1718893,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-2428650,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-2442929,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-3153452,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-6104898,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-6154244,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-7523474,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-7534932,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-7542531,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-7586235,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-8800300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-9312403,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-9457475,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-9574822,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-9729553,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17023511-9729554
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0022-3751
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
577
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1043-51
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:17023511-Adult,
pubmed-meshheading:17023511-Blood Pressure,
pubmed-meshheading:17023511-Enzyme Inhibitors,
pubmed-meshheading:17023511-Erythrocytes,
pubmed-meshheading:17023511-Female,
pubmed-meshheading:17023511-Hot Temperature,
pubmed-meshheading:17023511-Humans,
pubmed-meshheading:17023511-Laser-Doppler Flowmetry,
pubmed-meshheading:17023511-Male,
pubmed-meshheading:17023511-NG-Nitroarginine Methyl Ester,
pubmed-meshheading:17023511-Nitric Oxide Donors,
pubmed-meshheading:17023511-Nitric Oxide Synthase,
pubmed-meshheading:17023511-Nitroprusside,
pubmed-meshheading:17023511-Receptors, Neurokinin-1,
pubmed-meshheading:17023511-Regional Blood Flow,
pubmed-meshheading:17023511-Skin,
pubmed-meshheading:17023511-Stress, Physiological,
pubmed-meshheading:17023511-Substance P,
pubmed-meshheading:17023511-Vasodilation
|
pubmed:year |
2006
|
pubmed:articleTitle |
Neurokinin-1 receptor desensitization attenuates cutaneous active vasodilatation in humans.
|
pubmed:affiliation |
Department of Human Physiology, 122 C Esslinger Hall, 1240 University of Oregon, Eugene, OR 97403, USA.
|
pubmed:publicationType |
Journal Article
|